Florian Eichler, MD
Enriched profileProfessor of Neurology at Harvard Medical School · Massachusetts General Hospital
Florian Eichler is Professor of Neurology at Harvard Medical School at Massachusetts General Hospital. OpenAlex indexes 301 publications with 8,708 citations (h-index 50); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 24 Oct 2026
Florian S. Eichler, MD, is Professor of Neurology at Harvard Medical School at Massachusetts General Hospital. The public record shows 301 publications with 8,708 citations (h-index 50), centered on Lysosomal Storage Disorders Research, Metabolism and Genetic Disorders, Hereditary Neurological Disorders. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 6 companies, 5 NIH-funded awards (2006–2016).
- Most recent indexed publication: 2026 · Neurology. Genetics
- Top research focus: Lysosomal Storage Disorders Research
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 102.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy
Sponsor: Massachusetts General Hospital
- Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
Sponsor: Massachusetts General Hospital
- A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
Sponsor: Aspa Therapeutics
Industry payments
Updated 24 Oct 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ACADIA Pharmaceuticals IncProgram year20253 payments
- SANOFI US SERVICES INC.Program year20252 payments
- Mirum Pharmaceuticals, Inc.Program year20252 payments
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
62.5%Nonergot Dopamine Agonist62.5%Pramipexole Dihydrochloride100%Part D<11 patientsMetabolism & gastrointestinal
37.5%Bile Acid37.5%Chenodal100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 24 Oct 2026
5 NIH research awards on record, funded 2006–2016 per NIH RePORTER. The latest:
- Global Leukodystrophy Initiative Clinical Trials Network (GLIA- CTN)
Children'S Hosp of Philadelphia
FY2026$1,559,516U54NS115052 - Global Leukodystrophy Initiative Clinical Trials Network (GLIA- CTN)
Children'S Hosp of Philadelphia
FY2026$245,671U54NS115052 - Project 4: an observational study in parallel to a gene therapy trial in Canavan
Children'S Hosp of Philadelphia
FY2026$222,787U54NS115052
Congress activity
Updated 24 Oct 2026
1 congress contribution (2023) across ENDO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Neuropathologic Features of Adult-Onset Progressive Leukodystrophy Due to KARS Pathogenic Variants: A Case Report.
Neurology. Genetics
Article2026
Most-cited works
by citation count (OpenAlex)- 01Hematopoietic Stem-Cell Gene Therapy for Cerebral AdrenoleukodystrophyArticle606 citations2017
- 02Cerebral White MatterArticle487 citations2008
- 03
- 04
- 05Case definition and classification of leukodystrophies and leukoencephalopathiesArticle265 citations2015
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
Editorial & leadership roles
journal and society appointments- Director
leukodystrophy service and Center for Rare Neurological Diseases, Massachusetts General Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →glia-ctn.rarediseasesnetwork.org ↗ - Chair
Rare Disease Think Tank at MGH
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →glia-ctn.rarediseasesnetwork.org ↗ - Founder
ALD Connect (international consortium, patient-powered research network)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →glia-ctn.rarediseasesnetwork.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bioengineer.org ↗
Secondary affiliations
appointments beyond the home institution- Harvard Medical School
associate professor of neurology (per network page; the MGB profile says Professor)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →glia-ctn.rarediseasesnetwork.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
Andrew Zhu, MD, PhD
Massachusetts General Hospital
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine